Sunshine Biopharma, Inc. (SBFM)
USD 2.75
(0.37%)
USD 2.75
(0.37%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.78 Million USD | 44.83% |
| 2022 | -8.67 Million USD | -255.47% |
| 2021 | -2.44 Million USD | -322.99% |
| 2020 | -576.87 Thousand USD | 10.09% |
| 2019 | -641.63 Thousand USD | 45.0% |
| 2018 | -1.16 Million USD | -36.09% |
| 2017 | -857.19 Thousand USD | 13.69% |
| 2016 | -993.1 Thousand USD | -27.28% |
| 2015 | -780.27 Thousand USD | 55.54% |
| 2014 | -1.75 Million USD | 9.35% |
| 2013 | -1.93 Million USD | -173.97% |
| 2012 | -706.68 Thousand USD | -27.05% |
| 2011 | -556.2 Thousand USD | -3.5% |
| 2010 | -537.38 Thousand USD | -3333.53% |
| 2009 | -15.65 Thousand USD | 39.99% |
| 2008 | -26.07 Thousand USD | -98.74% |
| 2007 | -13.12 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.26 Million USD | 6.09% |
| 2024 Q1 | -1.35 Million USD | -50.49% |
| 2023 Q3 | -779.47 Thousand USD | 21.24% |
| 2023 Q1 | -1.82 Million USD | 63.69% |
| 2023 Q2 | -989.62 Thousand USD | 45.89% |
| 2023 Q4 | -897.48 Thousand USD | -15.14% |
| 2023 FY | -4.78 Million USD | 44.83% |
| 2022 Q4 | -5.03 Million USD | -193.19% |
| 2022 Q2 | -695.79 Thousand USD | 43.12% |
| 2022 FY | -8.67 Million USD | -255.47% |
| 2022 Q1 | -1.22 Million USD | -337.49% |
| 2022 Q3 | -1.71 Million USD | -146.91% |
| 2021 Q3 | -496.25 Thousand USD | -27.7% |
| 2021 Q1 | -1.27 Million USD | -271.56% |
| 2021 Q4 | -279.63 Thousand USD | 43.65% |
| 2021 Q2 | -388.59 Thousand USD | 69.54% |
| 2021 FY | -2.44 Million USD | -322.99% |
| 2020 FY | -576.87 Thousand USD | 10.09% |
| 2020 Q4 | -343.31 Thousand USD | -410.22% |
| 2020 Q2 | -128.56 Thousand USD | -241.04% |
| 2020 Q3 | -67.28 Thousand USD | 47.66% |
| 2020 Q1 | -37.69 Thousand USD | 84.96% |
| 2019 FY | -641.63 Thousand USD | 45.0% |
| 2019 Q1 | -120.8 Thousand USD | 64.02% |
| 2019 Q2 | -66.19 Thousand USD | 45.2% |
| 2019 Q3 | -202.64 Thousand USD | -206.12% |
| 2019 Q4 | -250.59 Thousand USD | -23.66% |
| 2018 FY | -1.16 Million USD | -36.09% |
| 2018 Q4 | -335.76 Thousand USD | 61.47% |
| 2018 Q3 | -871.51 Thousand USD | -52.64% |
| 2018 Q2 | -570.95 Thousand USD | -242.51% |
| 2018 Q1 | -166.69 Thousand USD | -2.79% |
| 2017 Q4 | -162.17 Thousand USD | -42.5% |
| 2017 Q3 | -113.8 Thousand USD | 75.9% |
| 2017 Q2 | -472.21 Thousand USD | -333.27% |
| 2017 Q1 | -108.99 Thousand USD | 67.57% |
| 2017 FY | -857.19 Thousand USD | 13.69% |
| 2016 Q4 | -336.09 Thousand USD | -189.7% |
| 2016 FY | -993.1 Thousand USD | -27.28% |
| 2016 Q3 | -116.01 Thousand USD | 75.38% |
| 2016 Q2 | -471.31 Thousand USD | -576.38% |
| 2016 Q1 | -69.68 Thousand USD | 60.01% |
| 2015 Q2 | -368.15 Thousand USD | -194.94% |
| 2015 Q3 | -113.05 Thousand USD | 69.29% |
| 2015 Q4 | -174.24 Thousand USD | -54.12% |
| 2015 FY | -780.27 Thousand USD | 55.54% |
| 2015 Q1 | -124.82 Thousand USD | 59.25% |
| 2014 Q3 | -277.42 Thousand USD | 63.76% |
| 2014 FY | -1.75 Million USD | 9.35% |
| 2014 Q2 | -765.51 Thousand USD | -88.61% |
| 2014 Q4 | -306.3 Thousand USD | -10.41% |
| 2014 Q1 | -405.87 Thousand USD | 40.78% |
| 2013 Q2 | -152.59 Thousand USD | 83.47% |
| 2013 Q1 | -922.89 Thousand USD | -390.23% |
| 2013 Q4 | -685.41 Thousand USD | -285.75% |
| 2013 FY | -1.93 Million USD | -173.97% |
| 2013 Q3 | -177.68 Thousand USD | -16.44% |
| 2012 Q3 | -376.4 Thousand USD | -266.54% |
| 2012 Q2 | -102.69 Thousand USD | -161.14% |
| 2012 Q4 | -188.25 Thousand USD | 49.99% |
| 2012 Q1 | -39.32 Thousand USD | 89.43% |
| 2012 FY | -706.68 Thousand USD | -27.05% |
| 2011 Q4 | -372.05 Thousand USD | -219.52% |
| 2011 Q3 | -116.44 Thousand USD | -606.13% |
| 2011 Q1 | -49.21 Thousand USD | 88.47% |
| 2011 FY | -556.2 Thousand USD | -3.5% |
| 2011 Q2 | -16.49 Thousand USD | 66.49% |
| 2010 Q2 | -1.58 Million USD | -4483.28% |
| 2010 Q4 | -426.94 Thousand USD | -128.23% |
| 2010 FY | -537.38 Thousand USD | -3333.53% |
| 2010 Q3 | 1.51 Million USD | 195.23% |
| 2010 Q1 | -34.64 Thousand USD | 0.0% |
| 2009 FY | -15.65 Thousand USD | 39.99% |
| 2009 Q3 | -32 Thousand USD | -516.55% |
| 2009 Q2 | -5191.00 USD | -110.16% |
| 2009 Q1 | -2470.00 USD | 26.33% |
| 2008 Q3 | -4638.00 USD | -9.31% |
| 2008 Q4 | -3353.00 USD | 27.71% |
| 2008 FY | -26.07 Thousand USD | -98.74% |
| 2008 Q1 | -10.78 Thousand USD | -376.03% |
| 2008 Q2 | -4243.00 USD | 60.65% |
| 2007 Q4 | -2265.00 USD | 74.23% |
| 2007 FY | -13.12 Thousand USD | 0.0% |
| 2007 Q3 | -8788.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Theratechnologies Inc. | -10.62 Million USD | 54.97% |
| Harrow Health, Inc. | 580 Thousand USD | 925.052% |
| Dynavax Technologies Corporation | -37.02 Million USD | 87.077% |
| Biofrontera Inc. | -22.67 Million USD | 78.898% |
| Cronos Group Inc. | -81.37 Million USD | 94.119% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -1.793% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 102.289% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 87.778% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 137.882% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 22.952% |
| Radius Health, Inc. | -3.92 Million USD | -21.918% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -35.685% |
| DURECT Corporation | -36.88 Million USD | 87.026% |
| ProPhase Labs, Inc. | -21.61 Million USD | 77.859% |
| Safety Shot Inc | -12.18 Million USD | 60.725% |
| Phibro Animal Health Corporation | 53.31 Million USD | 108.976% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -90.254% |
| Alvotech | -354.86 Million USD | 98.651% |
| Assertio Holdings, Inc. | -243.53 Million USD | 98.035% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 9.18% |
| Rockwell Medical, Inc. | -6.67 Million USD | 28.256% |
| Procaps Group S.A. | 52.32 Million USD | 109.146% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 96.998% |
| SCYNEXIS, Inc. | 72.66 Million USD | 106.585% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 8.921% |
| Viatris Inc. | 766.2 Million USD | 100.625% |
| OptiNose, Inc. | -22.74 Million USD | 78.964% |
| SIGA Technologies, Inc. | 83.62 Million USD | 105.723% |
| Tilray Brands, Inc. | -174.74 Million USD | 97.262% |
| PetIQ, Inc. | 60.01 Million USD | 107.974% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -0.0% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 101.907% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -10.354% |
| Alimera Sciences, Inc. | -1.47 Million USD | -225.309% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 102.866% |
| Silver Spike Investment Corp. | 7.34 Million USD | 165.194% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 18.788% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 138.206% |
| Journey Medical Corporation | -2.07 Million USD | -130.839% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 64.859% |
| Alpha Teknova, Inc. | -35.56 Million USD | 86.544% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 69.313% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 151.284% |
| PainReform Ltd. | -9.58 Million USD | 50.07% |
| Cosmos Health Inc. | -21.83 Million USD | 78.08% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 96.529% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 43.854% |
| Embecta Corp. | 221.5 Million USD | 102.16% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -1.025% |
| Talphera, Inc. | -16.88 Million USD | 71.666% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 105.458% |
| Incannex Healthcare Limited | -30.04 Million USD | 84.071% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 76.133% |
| Shineco, Inc. | -17.06 Million USD | 71.96% |
| Procaps Group, S.A. | 38.97 Million USD | 112.278% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 110.188% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 68.313% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 101.312% |
| Alvotech | -354.86 Million USD | 98.651% |
| Hempacco Co., Inc. | -8.81 Million USD | 45.697% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 108.952% |
| Bright Green Corporation | -8.89 Million USD | 46.18% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 96.924% |
| Kamada Ltd. | 10.06 Million USD | 147.549% |
| Indivior PLC | -4 Million USD | -19.632% |
| Evoke Pharma, Inc. | -7.43 Million USD | 35.603% |
| Flora Growth Corp. | -50.35 Million USD | 90.497% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 76.133% |
| Evolus, Inc. | -49.23 Million USD | 90.28% |
| HUTCHMED (China) Limited | 18.37 Million USD | 126.042% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 102.429% |
| Akanda Corp. | -10.05 Million USD | 52.392% |